Europe - FRA:PFE - US7170811035 - Common Stock
The current stock price of PFE.DE is 21.27 EUR. In the past month the price decreased by -5.54%. In the past year, price decreased by -14.39%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 43.01 | 779.22B | ||
| 1LLY.MI | ELI LILLY & CO | 41.13 | 745.05B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.51 | 440.74B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 18.04 | 392.27B | ||
| JNJ.DE | JOHNSON & JOHNSON | 18.04 | 392.27B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.11 | 241.64B | ||
| 1SAN.MI | SANOFI | 11.48 | 212.63B | ||
| NOT.DE | NOVARTIS AG-REG | 14.01 | 210.70B | ||
| SNW.DE | SANOFI | 11.37 | 210.51B | ||
| SAN.PA | SANOFI | 11.22 | 207.77B | ||
| 1NOVN.MI | NOVARTIS AG-REG | 13.77 | 207.14B | ||
| NOV.DE | NOVO NORDISK A/S-B | 12.14 | 180.23B |
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK US
Employees: 81000
Phone: 12127332323
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
The current stock price of PFE.DE is 21.27 EUR. The price decreased by -0.58% in the last trading session.
PFIZER INC (PFE.DE) has a dividend yield of 7.01%. The yearly dividend amount is currently 1.46.
PFE.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
PFIZER INC (PFE.DE) operates in the Health Care sector and the Pharmaceuticals industry.
You can find the ownership structure of PFIZER INC (PFE.DE) on the Ownership tab.
ChartMill assigns a technical rating of 2 / 10 to PFE.DE. When comparing the yearly performance of all stocks, PFE.DE is a bad performer in the overall market: 84.36% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to PFE.DE. PFE.DE has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months PFE.DE reported a non-GAAP Earnings per Share(EPS) of 2.95. The EPS increased by 151.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.84% | ||
| ROA | 5.22% | ||
| ROE | 12.12% | ||
| Debt/Equity | 0.65 |
30 analysts have analysed PFE.DE and the average price target is 25.45 EUR. This implies a price increase of 19.64% is expected in the next year compared to the current price of 21.27.
For the next year, analysts expect an EPS growth of -0.3% and a revenue growth -0.06% for PFE.DE